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Leucine-rich repeat-containing G protein-coupled receptors were identified by the unique
nature of their long leucine-rich repeat extracellular domains. Distinct from classical G
protein-coupled receptors which act via G proteins, LGR4 functions mainly through
Wnt/β-catenin signaling to regulate cell proliferation, differentiation, and adult stem cell
homeostasis. LGR4 is widely expressed in tissues ranging from the reproductive system,
urinary system, sensory organs, digestive system, and the central nervous system,
indicating LGR4 may have multiple functions in development. Here, we focus on the
digestive system by reviewing its effects on crypt cells differentiation and stem cells
maintenance, which are important for cell regeneration after injury. Through effects on
Wnt/β-catenin signaling and cell proliferation, LGR4 and its endogenous ligands, R-
spondins, are involved in colon tumorigenesis. LGR4 also contributes to regulation of
energy metabolism, including food intake, energy expenditure, and lipid metabolism, as
well as pancreatic β-cell proliferation and insulin secretion. This review summarizes the
identification of LGR4, its endogenous ligand, ligand–receptor binding and intracellular
signaling. Physiological functions include intestinal development and energy metabolism.
The potential effects of LGR4 and its ligand in the treatment of inflammatory bowel
disease, chemoradiotherapy-induced gut damage, colorectal cancer, and diabetes are
also discussed.
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Introduction
Leucine-rich repeat-containing G protein-coupled receptors (LGRs) are a distinct group of highly
conserved proteins of the GPCRs family, characterized by a large extracellular domain (ectodomain)
that harbors multiple copies of leucine-rich repeats (LRRs) (1). LRRs represent amphipathic
sequences with leucine as the predominant hydrophobic residue and are important for pro-
tein–protein interaction (2). The packing of similar repeats allows the formation of a specific
hydrogen bond network between neighboring repeats to form a unique tertiary structure (3). LRRs
are involved in ligand binding (4), connected via a cysteine-rich region to a seven-transmembrane
(TM) domain responsible for heterotrimeric G protein activation (5).
LGRs are divided into three subgroups (groupsA–C) (1, 6). GroupA receptors include FSH recep-
tor (LGR1), LH receptor (LGR2), and TSH receptor (LGR3), which recognize follicle-stimulating
hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH), respectively
(7, 8). These receptors contain seven to nine LRRs in their ectodomains and long hinge regions
connecting the LRR domains to TM domains. Group C LGRs have similar number of LRRs but
contain a low-density lipoprotein receptor class A domain motif at the N terminus and a short
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hinge region between the LRR domain and the 7TM domain.
Group C LGRs include RXFP receptor 1 (LGR7) and RXFP recep-
tor 2 (LGR8), recognizing relaxin and INSL3 (insulin-like peptide
3), respectively (1, 7, 8). The group B receptors include LGR4,
LGR5, and LGR6, which are characterized by a long ectodomain
containing 17 LRR repeats (6, 8) flanked by the N-terminal
LRRNT region and the C-terminal LRRCT region (8). Group B
receptors play crucial roles in embryonic development and are
involved in several types of cancer (9). They have also drawn
significant attention recently because of their roles in adult stem
cells, especially when LGR5 and LGR6were identified as stem cells
markers in multiple adult tissues (10–12).
The ligands of LGR4-6 remained unidentified for a prolonged
time. In 2011, the secreted R-spondin proteins (Rspo1-4) were
identified as the endogenous ligands for these receptors to regulate
cell proliferation, differentiation, and adult stem cell maintenance
through the activation ofWnt signaling pathways (13, 14). Details
on the binding between R-spondins and LGRs, and the subse-
quent intracellular signaling pathways are still under investiga-
tion. Recent studies have also revealed a relationship between
LGR4 and energy metabolism in areas ranging from food intake
and obesity to lipid metabolism.
Identification of LGR4
In 1998, based on the knowledge that large G protein-coupled
seven-TM receptors for LH, FSH, and TSH contain LRRs which
interact with glycoprotein ligands, and the theory that the puta-
tive glycoprotein hormone receptor sequences are conserved in
Drosophila and sea anemone (15, 16), human sequences related to
the sea anemone and Drosophila glycoprotein hormone receptors
(15, 16) were sought using expression sequence tags. Fragments
of two new mammalian receptors in the subfamily of leucine-
rich repeat-containing G protein-coupled receptors (LGR) were
identified. Adding to the three known LGRs, these two new
mammalian receptors were named LGR4 and LGR5 (17).
The full-length cDNAs for these novel receptors were isolated
using RT-PCR and repeated screening of sub-libraries from rat
ovary or human placenta enriched with each receptor cDNA.
LGR4 cDNA from rat ovary consists of 3,504 base pairs with a
predicted open reading frame (ORF) of 951 amino acids, whereas
LGR5 from human placenta has 4,208 base pairs with a 907 amino
acids ORF (17). Similar to three known glycoprotein hormone
(LH, FSH, and TSH) receptors, LGR4 and LGR5 are characterized
by multiple LRR sequences. The ectodomains of LGR4 and LGR5
are composed of 17 LRRmotifs, each 22–24 amino acids in length
(17). In contrast to the restricted tissue expression pattern of
known gonadotropin and TSH receptors, these new receptors
were found in multiple tissues (17).
Identification of this expanding family of LGRs promoted stud-
ies to identify putative ligands and to unravel the evolutionary
origin of proteins in this subfamily of receptors.
Ligands of LGR4
The R-spondin (Rspo) protein family is a group of four secreted
proteins (Rspo1-4) that were isolated as strong potentiators of
Wnt/β-catenin signaling (18–20). These proteins share 40–60%
identity between each other and a similar structure with a
cysteine-rich furin-like domain preceding a thrombospondin-like
domain (21, 22). Despite their similarity, the four known Rspos
serve in different developmental events. Rspo1 regulates sexual
development; Rspo2 modulates development of limbs, lungs, and
hair follicles; Rspo3 is involved in placenta development; and
Rspo4 affects nail development (23).
Beginning in 2011, several groups have demonstrated that R-
spondins (Rspo 1-4) are endogenous ligands for LGR4 and LGR5.
A fusion gene construct (mRspo1-Fc), encoding the mature form
of mouse Rspo1 and the Fc fragment of mouse IgG2a, is biologi-
cally active (24).When incubating cells expressing LGR4 or LGR5
withmRspo1-Fc at 4°C (to prevent internalization), a strong signal
indicative of binding was observed on the cell surface. Whole-
cell competition binding assay showed that recombinant Rspo1-4
could compete with mRspo1-Fc for binding to LGR4 and LGR5
(25). The results of binding analyses indicate that Rspo1-4 can
bind to LGR4 and LGR5 with Rspo2 having the highest affinity
to both receptors. Using β-catenin-responsive reporter assay (26),
cells transfectedwith LGR4 or LGR5displayed a dramatic increase
in the potencies of Rspo1-4, ranging from 10- to 1,000-fold, on
Wnt/β-catenin signaling in the presence of exogenousWnt3a (25).
Experiments using an unbiased screening strategy have also
identified LGR4 and LGR5 as receptors of Rspo proteins (27).
Depletion of LGR4 completely abolishes Rspo1 signaling, while
overexpression of LGR4 potentiates Rspo1-4 signaling. Rspo1
interacts with the extracellular domain of LGR4 and LGR5 (27).
Further, Rspo1 does not induce coupling between LGR4 and
heterotrimeric G proteins, suggesting that LGR4 transmits Rspo
signaling through a novel undefined mechanism independent of
G protein signaling. This likely contributes to the relatively long
time taken to deorphanize LGR4. This study further supports
the conclusion that Rspo potentiates Wnt/β-catenin signaling
through LGR4 and LGR5, which is described in detail in Section
“Intracellular Signaling of LGR4.”
Binding of R-Spondins to LGR4/5
The extracelluar domain (ECD) of LGR4 exhibits a twisted
horseshoe-like structure. Rspo1 adopts a flat and fold architecture
and is bound in the concave surface of LGR4 through electro-
static and hydrophobic interactions (28). All the Rspo1-binding
residues are conserved in LGR4-6, suggesting that LGR4-6 bind
R-spondins through an identical surface. R-spondin proteins have
the same structural organization. They have two adjacent furin-
like domains (FU1 and FU2) at the amino terminus, and a throm-
bospondin (TSP) domain close to the carboxyl terminus (29)
(Figure 1). Sequence similarities of furin-like domains and TSP
domain of four Rspo proteins from different species are high,
for example, the identities of Rspo1 protein sequences between
human and mouse is 94% (from Pubmed Blast), suggesting R-
spondin proteins have conserved functions. A fragment contain-
ing two furin-like domains of R-spondin is sufficient to activate
Wnt signaling, and both furin-like domains are required for the
signaling activity of R-spondin (18, 30). In addition to LGR4/5,
various membrane proteins have been reported to bind to R-
spondin, including Wnt receptors Frizzled (20) and LRP6 (20,
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FIGURE 1 | Rspondin1-LGR4 linear sructure illustration. Linear structure of
Rspondin1 and LGR4-ECD. Rspondin1 consists of a signal peptide (SP), two
adjacent cysteine-rich furin-like domains (FU1/2), a common thrombospondin
(TSP-1) motif and a basic amino acid-rich (BR) domain. LGR4 ectodomain
(LGR4-ECD) are characterized by 17 leucine-rich repeats (LRRs) flanked by the
N-terminal LRRNT region and the C-terminal LRRCT region. The main
interacting residues of LGR4-ECD are LRR3-9 [refer to Ref. (4, 5) for detailed
information].
31), Kremen (32), Syndecan 4 (33), and membrane E3 ubiquitin
ligases ZNRF3/RNF43 (34). For example, Xie et al. reported that
mutation of furin-like domain 1 (FU1) (R66A orQ71A) abolished
the interaction between Rspo1 and ZNRF3, without affecting the
interaction between Rspo1 and LGR4, while mutation of two
residues of the furin-like domain 2 (FU2) (F106A or F110A)
blocked the interaction between Rspo1 and LGR4, without affect-
ing the interaction between Rspo1 and ZNRF3 (29). These results
suggest that Rspo1 binds to ZNRF3 and LGR4 through distinct
domains: the FU1 domain is involved in ZNRF3 binding, whereas
the FU2 domain is involved in LGR4 binding. In the absence of
Rspo, ZNRF3/RNF43 ubiquitinates the FZD receptors for degra-
dation, resulting in low Wnt signaling activity. Rspo1 can bind to
bothZNRF3 and LGR4 to induce their dimerization (34). In the R-
spondin-LGR4–ZNRF3 complex, LGR4 serves as the engagement
receptor to recruit R-spondin to ZNRF3. ZNRF3 serves as the
effector receptor. Inhibition of ZNRF3 by R-spondin potentiates
Wnt signaling. The R-spondin-LGR4/5–ZNRF3/RNF43 complex
represents a fascinating example of a secreted protein regulating
receptor turnover by targetingmembrane E3 ubiquitin ligases (29)
(Figure 2).
Intracellular Signaling of LGR4
Studies have suggested that interaction betweenRspo proteins and
LGR4potentiates canonicalWnt/β-catenin signaling, but does not
activate Gi, Gs, or Gq pathways. Structurally, LGR4 and LGR5 are
quite similar to other LRR-containing GPCRs which are coupled
to heterotrimericG protein signaling by ligand binding. The intra-
cellular signaling pathway by which Rspo and LGR4 potentiate
Wnt/β-catenin signaling remains largely unknown.
By examining proteins co-immunoprecipitated with LGR4,
Kendra et al. identified IQGAP1 and IQGAP3 as potential
candidates that could mediate the intracellular signaling of
Rspo–LGR4 to the Wnt signalosome (35). Interaction between
LGR4 and IQGAP1 occurs between the 7TM domain of LGR4
and the rasGAP-related domain (GRD) of IQGAP1. Stimula-
tion of LGR4 by Rspos increases the affinity of IQGAP1 to
FIGURE 2 | LGR4-Wnt/β-catenin signaling pathway. In the absence of
Rspos, membrane E3 ubiquitin ligases ZNRF3/RNF43 ubiquitinates the
(Frizzled) FZD receptor for degradation, Wnt signaling activity is blunted.
Cytoplasmic β-catenin is degradated by the β-catenin destruction complex,
leading to no β-catenin complex formation with T-cell transcription factor (Tcf)
and subsequent silence in active transcriptional response. In the presence of
Rspos, simultaneous binding of LGR4 and ZNRF3 inhibits the ubiquitination of
FZD receptor, meanwhile, LGR4 recruits IQGAP1 and increases its affinity to
DVL, leading to the formation of supercomplex with Wnt signalosome. This
allows β-catenin accumulation in cytoplasm, followed by translocation into the
nucleus and activation of TCF target genes. LGR4, leucine-rich
repeat-containing G protein-coupled receptors 4; ZNRF3, zinc and ring finger
3; FZD, Frizzled class receptor; Rspos, R-spondins; LRP5/6, low-density
lipoprotein receptor-related protein 5/6; Ubi, ubiquitination; DVL, disheveled.
disheveled (DVL), leading to the formation of a supercomplex
between Rspo–LGR4 and the Wnt signalosome (35). Potentia-
tion of Wnt signaling requires the MEK1/2-binding domain of
IQGAP1, which provides the hint that LGR4-bound IQGAP1
brings in MEK1/2 to phosphorylate LRP6. In this configuration,
IQGAP1 not only engages MEK1/2 to phosphorylate LRP5/6
but significantly enhance canonical Wnt signaling. IQGAP1
also recruits actin-polymerization complexes through binding to
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neural Wiskott–Aldrich syndrome protein (N-WASP) and mDia1
to coordinate actin dynamics (35), which is critical to the control
of cell adhesion and migration (36–38). This dual-mechanism
model provides an explanation for the pleiotropic functions of
Rspo–LGR4 signaling in normal and cancer development, par-
ticularly for the crucial role of LGR4 in tubule elongation and
branching in multiple organs (Figure 2).
Other signaling pathways have also been reported for LGR4.
LGR4 (GPR48) participates in the development of the male
epididymis and efferent ducts through regulation of ERalpha
expression via the cAMP/PKA signaling pathway (39). LGR4
(GPR48) knockout suppressed ATF4, a key transcription fac-
tor in erythropoiesis, in midgestation fetal livers through the
cAMP–PKA–CREB pathway, suggesting that GPR48 regulates
erythropoiesis through ATF4 (40).
LGR4 in Intestinal Development
Expression in Stem Cells
A common feature of the LGR4/5/6 receptors is their expression
in distinct types of adult stem cells. LGR5 is a marker for resident
stem cells in Wnt-dependent compartments, including the small
intestine, colon, stomach, and hair follicles (9). LGR6 serves as a
marker of multipotent stem cells in the epidermis (12). LGR4 is
widely expressed in proliferating cells (41).
The expression of LGR4 was investigated using an animal
model with disrupted LGR4 gene by a trap vector carrying
two biological markers, β-geo (a fusion between bacterial β-
galactosidase and neomycin phosphotransferase) and a placental
alkaline phosphatase (PLAP) (42). Due to the perinatal lethality of
homozygosity for this insertion, LacZ and PLAP activity patterns
in heterozygous mice were investigated. In embryonic day (E) 14
embryos, LGR4was strongly labeled in eyes, tongue surface, olfac-
tory epithelium and vomeronasal organ, ribs, esophagus, cartilage
condensation of vertebrae, umbilical cord, medulla oblongata,
pons, and Rathke’s pouch (41). In adults, strong LacZ staining
signals were detected in cartilage, kidney, adrenal gland, salivary
glands, and testis, while lower intensity was observed in a wide
range of organs (41).
LGR4 in Digestive System
At E15 and at birth, LacZ activity was detected in the pseudo-
stratified epithelium and intervillus progenitors, respectively. In
adults, epithelial expression of LGR4 was found along the crypts,
but not in the villi by using X-gal staining and in situ hybridization
(41). In the crypts, LGR4 expression was found above the Paneth-
cell zone, in the transit-amplifying (TA) cell region, in crypt
basal columnar cells, and co-localized with some Paneth cells.
Outside the epithelium, LGR4 is expressed in the mesenchyme
and smooth-muscle layers, intestinal subepithelial myofibroblasts
and enteric neurons. A similar expression patternwas found in the
duodenum and colon (41).
Another study has validated the presence of LGR4 immunore-
activity in Paneth cells whichwere distinguished by large secretory
granules in the cytoplasm (43). Similar staining was also noted in
crypt stem cells which are sandwiched between Paneth cells (44).
No significant staining of LGR4 was found beyond the cells in
the crypts. The intense LGR4 positive staining signal observed in
Paneth cells and stem cells in the crypt region of mouse intestine
were consistent with that of LGR4mRNAdistribution determined
using lac-Z alleles (45). In the mouse colon, only diffuse, weak
LGR4 immunoreactivity in the cytoplasm was found in all cells
from the base to the epithelial surface, with slightly stronger
staining at the surface. No distinct staining was found in stem cells
located at the crypt base in colon (43).
Intense LGR4 immunoreactivity was also found in the pancre-
atic isletswith no staining in acinar cells. Co-staining of anti-LGR4
and anti-insulin antibody onmouse pancreas sections showed that
LGR4was expressed in all β-cells (43).Moreover, among the three
LGR receptors, only LGR4 is expressed in the pancreas based on
the analysis of EST data and Northern blotting (46). The intense
staining of LGR4 in the islets strongly suggests that LGR4mediates
the effects of its endogenous ligands in the pancreas.
LGR4 in Intestinal Development
Intestinal crypts contain LGR5+ stem cells and their TA daughter
cells, as well as terminally differentiated Paneth cells. Cells exiting
crypts terminally differentiate into enterocytes, goblet cells, M-
cells, Tuft cells, and enteroendocrine cells, andmove up the flanks
of the villi to undergo apoptosis upon reaching the villus tips (47).
Paneth cells escape the crypt–villus flow by migrating to crypt
bottoms where they persist for several weeks (48).
Mice homozygous for the gene trap LacZ knock-in allele,
referred to as “Lgr4 knockout”, displayed a hypomorphic pheno-
type with intrauterine growth retardation and perinatal lethality.
Heterozygous mice with a LacZ gene trap knocked in the Lgr4
locus (42) have also been used. Although the timing of crypt
development was normal in Lgr4-knockout mice, reduction in the
crypt depth and epithelial cell proliferation were obvious from
postnatal day (P) 15 (49). Differentiation of absorptive, enteroen-
docrine, and goblet-cell lineages was not modified significantly.
However, defects in Paneth-cell differentiation were observed at
all postnatal stages, with reduction in Paneth-cell number at P21
and decreased expression of the terminal differentiation markers
P-lyzozyme and cryptdin 4 (49), suggesting a key role for LGR4
in postnatal epithelial cell proliferation and terminal Paneth-cell
differentiation.
Ex vivo experiments have demonstrated that LGR4 is required
for the maintenance of crypt stem cells. Crypts cultured from
P15 wild-type or heterozygous mice differentiated into multi-
fingered organoids after 3 days in culture. After generation
of hollow spheres containing mainly stem and TA cells (day
0.5–1), structures grown from P15 Lgr4-knockout intestine
did not increase further in size and became filled with cellular
material (days 1.5–2) (49). Lgr4-knockout organoids started to
disaggregate between days 2 and 3, and died before day 7. The
same phenotype was observed in Lgr4-knockout progenitors
isolated from newborn mice, when fully differentiated Paneth
cells are not yet present (49).
LGR4 in Energy Metabolism
The presence of LGR4 in hypothalamic energy homeostatic
areas and its co-localization with key energy homeostatic neu-
rons suggests that it may contribute to the regulation of energy
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homeostasis. In situ hybridization revealed that LGR4 mRNA
is highly expressed in the cortex, hippocampus, amygdala, and
the hypothalamus (41). In the cortex, LGR4 mRNA is expressed
in layers II and III. In the hippocampus, LGR4 is expressed
in CA1, CA2, CA3, and the dentate gyrus (DG).The habenu-
lar nuclei (Hbs) of the epithalamus also express LGR4. In the
amygdala, LGR4 mRNA is expressed with high levels in the
medial amygdaloid nucleus, posteroventral nucleus, and basal
lateral amygdaloid nucleus (41). In the hypothalamus, LGR4 is
expressed in the ventromedial hypothalamus (VMH), the arcu-
ate nucleus (ARC), median eminence (ME), and the ependymo-
cytes lining the third ventricle (50). The ME and ependymo-
cytes have the highest levels of LGR4 expression, followed by
VMH and ARC. The expression pattern of LGR4 in the VMH
overlaps that of brain-derived neurotrophic factor (BDNF) (51).
Double in situ hybridization showed that in the ARC, LGR4 is
expressed by most neuropeptide Y (NPY) neurons and proop-
iomelanocortin (POMC) neurons. NPY neurons express higher
levels of LGR4 compared with POMC neurons in the ARC. All
POMC neurons in the ME express LGR4 at the highest lev-
els. In the VMH, LGR4 is expressed by the majority of BDNF
neurons (50).
Rspo1 and Rspo3, ligands of LGR4, are expressed in hypotha-
lamic energy homeostatic areas (50). Their levels were down-
regulated by fasting and up-regulated by the satiety factor insulin,
indicating that they might be involved in the regulation of
energy homeostasis as anorexigenic factors. The inhibition of food
intake observed after intracerebroventricular injection ofRspo1 or
Rspo3 support this concept (50). Rspo1 ismore potent than Rspo3
in inhibiting food intake. Consistent with this observation, Rspo1
binds to LGR4 with an affinity higher than Rspo3 (25).
GPR48 (LGR4) is critical in development, and Gpr48 mutant
mice display early neonatal lethality. Wang et al. have estab-
lished the Gpr48 (LGR4) hypomorphic mutant mice by microin-
jecting gene trap-mutated Gpr48 ES cells into C57BL/6 blas-
tocysts. The insertion of the trap vector into intron 1 of the
Gpr48 gene resulted in approximately 90% knockdown efficiency
in the kidney and adrenal gland of adult LGR4 mutant mice.
Approximate half of LGR4 mutant newborns died within 28 h
after birth, but no further deaths occurred in the following 20 h
(52). Studies of the Lgr4-knockout mice have revealed a critical
role of LGR4 in lipid metabolism. Relative to wild-type mice
fed normal chow diet, both male and female Lgr4 mutant mice
exhibited decreased body weight and body fat content, includ-
ing epididymal white adipose tissue (eWAT) and inguinal WAT
(iWAT), whereas brown adipose tissue (BAT) content remained
unaltered (53). Consistent with the lean phenotype, Lgr4 mutant
mice showed improved glucose tolerance and reduced fasting total
cholesterol levels. When challenged with a high-fat diet (HFD),
both male and female Lgr4 mutant mice showed a resistance to
HFD-induced body weight gain, with improved glucose tolerance
and insulin sensitivity (53). Higher O2 consumption, CO2 pro-
duction, and body temperature indicated that energy expendi-
ture was elevated in Lgr4 mutant mice. Compared to the white,
large, and unilocular adipocytes comprising WAT in wild-type
mice, Lgr4 mutant mice showed reduced WAT mass with beige
color, smaller, and multilocular adipocytes containing increased
mitochondrion number. These results indicate an adipocyte phe-
notype transformation in Lgr4 mutant mice (52). Consistent
with this concept, Ucp1 and other thermogenic genes, includ-
ing Pgc-1α, Cidea, cytochrome c, Cpt2, and Nrf1, were signifi-
cantly increased in eWAT of Lgr4 mutant mice, and were further
enhanced under cold stress or isoprenaline treatment. Beige cell
markers CD137 and TMEM26 (54) were also increased in eWAT
of Lgr4 mutant mice after isoprenaline treatment. These results
demonstrate that Lgr4 ablation drives the acquisition of functional
brown-like adipocytes in the WAT depots, leading to increased
energy expenditure (52).
The association of LGR4 with human obesity has been demon-
strated by a case–control study of early-onset obesity in which
four SNPs, located in the encoding and flanking regions of
the LGR4 locus, were found to be significantly correlated with
body mass index. A low-frequency non-synonymous LGR4 vari-
ant (A750T) was identified more than twice as commonly in
obese patients when compared with controls (52). This site in
LGRs is highly conserved among different species, and consti-
tutively activated point mutations of the corresponding site in
LHR, TSHR, and FSHR have been reported (55–57). The A750T
variant showed higher stimulating activity of a CRE-luciferase
reporter than wild-type LGR4, suggesting a functional variation.
All these observations suggest a contribution of LGR4 to human
adiposity.
Another study based on the LGR4 mutant mice described
before also indicates a correlation between LGR4 and lipid
metabolism (58) in a circadian rhythm-related manner. Resting
energy expenditure (RER) is higher in the dark phase than in the
light phase in wild type (WT) mice (59), suggesting the existence
of a circadian rhythm in substrate utilization for energy during the
day, more glucose in the dark phase, and more lipid usage in the
light phase. In Lgr4 mutant mice, the RER was higher than that
of their WT littermates during the dark phase with no difference
during the light phase (57), suggesting that lack of LGR4 altered
the circadian rhythm of lipid metabolism. Lgr4-knockout mice
consumed less lipids but more sugar compared with WT mice
(60, 61). Lgr4 mutant mice exhibited higher plasma triglyceride
levels and lost the rhythmic pattern comparedwithWTmice. Lgr4
mutantmice also presented a change in plasmanon-esterified fatty
acid levels, reflected by lower plasma levels during the light phase
and higher levels in the dark phase in comparison with WTmice.
Interestingly, loss of LGR4 does not affect clock gene expression in
the liver. InWTmice, LGR4 expression in liver was higher during
the light phase than the dark phase, presenting a peak at ZT4 and
a nadir at ZT16, indicating a circadian rhythm. Lgr4 expression
levels in Lgr4 mutant mice were very low and amplitude was
dampened (57). Lack of LGR4 causes an arrhythmic plasma lipid
phenotype in mice.
Therapeutics Potential of Rspos-LGR4
Treatment for Inflammatory Bowel Disease
As defective epithelial restitution is an important risk factor
for inflammatory bowel disease (IBD), it is not surprising that
dysfunction of genes involved in intestinal development, prolif-
eration, and differentiation will increase susceptibility to IBD.
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When Lgr4 hypomorphicmice are subjected to the dextran sulfate
sodium (DSS)-induced IBD, a more severe colitis developed in
Lgr4 mutant mice than in WT sex-matched littermates. Higher
body weight loss, a hallmark of intestinal inflammation, was
observed in Lgr4 mutant mice. This observation was concor-
dant with a more severe anemia (45). Although the small intes-
tine is not the major target of DSS-induced tissue damage (62),
the relative length reduction was significantly increased in Lgr4
mutant mice, indicating critical functions of Lgr4 in the small
intestine. Almost all crypts throughout the small intestine were
lost in Lgr4 mutant mice but remained intact in WT littermates.
Histological examination showed dramatically increased signs
of colitis, which is characterized by the loss of crypts and the
infiltration of leukocytes into the colons of Lgr4 mutant mice
(45). Infiltration of neutrophils was significantly higher in the
colon of Lgr4mutant mice. Additionally, inflammatory cytokines,
such as TNFα, IL6, and IL1, were significantly increased in
Lgr4 mutant mice after DSS administration, suggesting a more
severe inflammatory response (45). Significant decreases in Ki67-
positive proliferating cells were observed in Lgr4mutant intestines
during tissue regeneration. No significant alteration of apopto-
sis was observed either in control conditions or in the recov-
ery period, indicating that LGR4 is responsible for epithelial
cell proliferation but not apoptosis during DSS-induced tissue
regeneration (45).
Human Rspo1 protein effectively increases survival and prolif-
eration of LGR5+ intestinal stem cells in vitro through activation
of Wnt/β-catenin signaling (63). The mitogenic activity of Rspo1
on intestinal stem cells may be useful in the therapy of IBD
because of its stimulating effect on crypt cell growth to accelerate
mucosal regeneration. In both acute and chronic phases of coli-
tis in mouse models, administration of Rspo1 protein preserves
mucosal integrity in both small and large bowel by stimulating
crypt epithelial cell mitosis (64).
Protective Effects of R-Spondin in
Chemoradiotherapy-Induced Gut Injury
Stimulation of Wnt/β-catenin signaling with Rspo1 can amelio-
rate 5-fluorouracil (5-FU) and radiation-induced gut damage,
including radiation-induced gastrointestinal syndrome (RIGS)
(64–66). Recently, Zhou et al. have found that combination of Slit2
andRspo1 could potentially protect gut from chemoradiotherapy-
induced damage (67). Slit is a secreted protein which func-
tions through the TM protein Roundabout (Robo) receptor as
a chemorepellent in axon guidance and neuronal migration,
and as an inhibitor in leukocyte chemotaxis (68). The ther-
apeutic dosage of 5-FU (19), a well-characterized chemother-
apy agent, markedly shortened villus length, reduced numbers
of LGR5+ intestinal stem cells, and Ki67+ transient amplify-
ing cells in jejunum. Using Lgr5–enhanced green fluorescent
protein (eGFP)–internal ribosome entry site (IRES)–CreERT2
(Lgr5–GFP) mice to detect the intestine stem cells (10), the
lethal dose of 5-FU has been found to abolish >90% of GFPhigh
intestinal stem cells. However, a 3-day treatment of rSlit2 or
rRspo1 alone protected 40% of GFPhigh stem cells. Combination
rRspo1 plus rSlit2 preserved 80% of GFPhigh intestinal stem cells,
indicating that Slit2 acts synergistically with Rspo, leading to
prolongation of overall survival after exposure to lethal doses of
chemotherapy (67).
ApcMin/+ mice with spontaneous intestinal adenomas were
treated with DSS to induce inflammation-related intestinal car-
cinogenesis, a murine model of multifactorial human colorectal
cancer (CRC) (69). Administration of DSS-treated ApcMin/+ mice
with rSlit2 or rRspo1 alone led to a 20–30% survival rate upon
the lethal dosage of 5-FU. Combination of rSlit2 and rRspo1 led
to a 60% survival rate (67), demonstrating functional cooperation
between Slit2 and Rspo1. Concomitant prolongations of the villus
length, augmentations of Lgr5+ stem cells and Ki67+ transient
amplifying cells in the jejunumwere observed when animals were
treated with a combination of rSlit2 plus rRspo1 (67).
R-Spondin Fusion Protein in the Treatment of
Colorectal Cancer
Colorectal cancer is the fourth most prevalent cancer, accounting
for over 50,000 deaths per year in the United States. Approxi-
mately 15% of CRCs have microsatellite instability arising from
defects in the DNA mismatch-repair system, whereas the other
85% of microsatellite-stable CRCs are the result of chromosomal
instability (70).
Using RNA-seq data, Seshagiri et al. have identified 36
rearrangements that result in gene fusions (71), including two
recurrent ones. The recurrent fusions found in microsatellite-
stable samples involve the R-spondin family members, Rspo2 and
Rspo3 (70). Both of them were expected to produce functional
Rspos protein. The expression of Rspo2 and Rspo3 in colon tumor
samples, containing the fusions, was elevated compared with
the tumor samples lacking R-spondin fusions (70). Furthermore,
all of the Rspo-positive fusion tumors expressed the potential
R-spondin receptors LGR4, LGR5, and LGR6. Additionally,
alteration of the Rspo2 gene is linked to CRC in a transposon-
based genetic screening in mice (72).Consistent with the elevated
expression of Rspo genes observed in human tumors, a 20-fold
increase in Rspo2 messenger RNA expression in a mouse tumor
carrying a transposon insertion near the Rspo2 transcription
start site was detected relative to adjacent normal tissue. These
observations indicate that the R-spondins may function as drivers
in human CRCs (70). Although further studies are required
to fully understand the role of R-spondin fusions in CRC
development, they represent attractive targets for antibody-based
therapy in CRC patients positive for R-spondin fusions. Other
therapeutic strategies that target downstream components of the
Wnt signaling cascade might be effective against tumors positive
for R-spondin fusions.
R-Spondin in the Treatment of Diabetes
The development of type 2 diabetes mellitus (T2DM) usually
requires the presence of insulin resistance, impaired β-cell func-
tion, and the loss of β-cells (73). Type 1 diabetes mellitus (T1DM)
is characterized by autoimmune-mediated destruction of β-cells.
Novel therapeutic approaches might include expanding β-cell
mass. As reported by Wong et al., Rspo1 enhances insulin mRNA
levels after stimulation for 12 h. Rspo1 can also regulate insulin
secretion in mouse islets. Static incubation of islets with Rspo1
for 2 h induced a significant increase in insulin secretion in a
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TABLE 1 |Roles of LGR4 in intestinal functions and energy metabolism, and
summary of the therapeutic potentials of Rspos-LGR4 system.
Roles of
LGR4
Physiological functions Therapeutics potentials
In intestine 1. Postnatal epithelial cell
proliferation and terminal
Paneth-cell differentiation
1. Inflammatory bowel disease
2. Chemoradiotherapy-induced
gut injury
2. Maintenance of crypt
stem cells
3. Colorectal cancer
In energy
metabolism
1. Inhibition of food intake 1. Obesity
2. Acquisition of functional
brown-like adipocytes in the
WAT depots in Lgr4 /  mice
2. Diabetes mellitus
3. Lipid metabolism
3. Association with human
obesity
4. Arrhythmic plasma lipid
phenotype in Lgr4 /  mice
glucose-independent manner (74). Treatment with recombi-
nant mouse Rspo1 also increases MIN6-cell proliferation. Rspo1
induced an increase in BrdU incorporation in insulin-positive
cells (74). When treated MIN6 cells were exposed to a mixture
of cytokines for 18 h, the level of activated, cleaved caspase3 was
significantly increased. The increase in cleaved caspase 3 was
prevented by pretreatment with Wnt3a, as well as by Rspo1. A
similar observation was made in dispersed murine β-cells. Treat-
ment with cytokines for 18 h significantly increased the number
of TUNEL-positive β-cells; pretreatment with Rspo1 significantly
reduced cytokine-induced apoptosis (74). These observations
suggest that Rspo1 may be a potential novel molecule for the
treatment of patients with T2DM or T1DM.
Conclusion
The importance of LGR4 and its ligands-Rspos in the regulation
of canonical and non-canonical Wnt signaling pathways has been
established in a variety of in vitro and in vivo studies using animal
models and human genetic analysis. Although significant progress
has been made in our understanding of how Rspo binds with
LGR4 and regulates the Wnt signaling pathway at the molecular
level, the following fundamental questions remain unanswered.
How does LGR4 interact with FZD (Wnt receptor) after bind-
ing with Rspo proteins? Does LGR4 have a specific intracellular
signaling pathway or simply function as a potentiator of Wnt
signaling? Additionally, discrepancy between gain and loss of
LGR4 function exists. While LGR4-knockout mice showed an
improvement in glucose metabolism, Rspo1 has been reported
to significantly induce β-cell proliferation and insulin secretion.
Further studies on the functions and signaling mechanisms of
the LGR4 and Rspo proteins will facilitate the development of
therapeutic strategy for human diseases, such as IBD, CRC, and
diabetes, by targeting Rspo-LGR4 (Table 1).
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